Clinical Trial Update: A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating GW597599B for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GW597599B

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED